Evidence map›Paper›PMID 34690353›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2022

Circulating fibroblast growth factor 21 links hemodynamics with kidney function in middle-aged and older adults: A mediation analysis.

Masahiro Matsui, Keisei Kosaki, Makoto Kuro-O, Chie Saito, Kunihiro Yamagata, Seiji Maeda

Abstract read
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Update on Hypertension Research in 2021.Hypertension research : official journal of the Japanese Society of Hypertension · 2022
    Review
  3. Neural afferents as potential targets to ameliorate FGF21-mediated sympathoexcitation.Hypertension research : official journal of the Japanese Society of Hypertension · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Masahiro MatsuiGraduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.
Keisei KosakiFaculty of Health and Sport Sciences, University of Tsukuba, Ibaraki, Japan.
Makoto Kuro-ODivision of Anti-aging Medicine, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.
Chie SaitoDepartment of Nephrology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Kunihiro YamagataDepartment of Nephrology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Seiji MaedaFaculty of Health and Sport Sciences, University of Tsukuba, Ibaraki, Japan. maeda.seiji.gn@u.tsukuba.ac.jp.
University of Tsukuba · JPJapan Society for the Promotion of Science · JPJichi Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Altered hemodynamics are commonly observed in individuals with declining renal function; however, the pathophysiological mechanisms linking renal dysfunction and hemodynamics have not been fully elucidated. Fibroblast growth factor 21 (FGF21), which upregulates sympathetic nerve activity, can alter systemic hemodynamics, and its level can increase as renal function declines. This study aimed to determine the associations among circulating FGF21 levels, hemodynamics, and renal function in middle-aged and older adults. In a total of 272 middle-aged and older adults (age range: 46-83 years), estimated glomerular filtration rate (eGFR), hemodynamics (brachial and aortic blood pressure and aortic pulse wave velocity [PWV]), and serum FGF21 levels were measured. For mediation analysis, hemodynamic parameters were entered as outcomes. eGFR or log-transformed urinary albumin and creatinine ratio (UACR) and log-transformed serum FGF21 levels were set as the predictors and mediator, respectively. According to multivariable regression models after adjusting for potential covariates, serum FGF21 levels were significantly associated with brachial systolic blood pressure (β = 0.140), pulse pressure (β = 0.136), and aortic PWV (β = 0.144). Mediation analyses showed that serum FGF21 levels significantly mediated the relationship of eGFR with brachial systolic blood pressure (indirect effect [95% confidence interval]: -0.032 [-0.071, -0.002]), pulse pressure (-0.019 [-0.041, -0.001]), and aortic PWV (-0.457 [-1.053, -0.021]) and the relationship of UACR with aortic PWV (7.600 [0.011, 21.148]). These findings suggest that elevated circulating FGF21 levels partially mediate the association of elevated blood pressure and/or aortic stiffness with renal dysfunction in middle-aged and older adults.

Indexed as

Fibroblast Growth FactorsMediation AnalysisVascular StiffnessAgedAged, 80 and overBlood PressureGlomerular Filtration RateHemodynamicsHumansKidneyMiddle AgedPulse Wave AnalysisFGF21 protein, humanfibroblast growth factor 21Fibroblast Growth FactorsArterial stiffnessBlood pressureInflammation.Renal dysfunctionSystemic hemodynamics

Identifiers

PMID34690353
OpenAlexW3210578999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.